1 / 11

Market Outlook on 2022 Ranirestat Market Healthcare Report

The entire market for microvascular complications of diabetes (MCD) diabetic nephropathy, retinopathy, and neuropathy is facing an extremely high level of unmet need across the 7MM (US, 5EU and Japan). Despite its enormous potential, the MCD market is facing the major global barrier in the sparsely populated pipeline. The diabetic retinopathy segment of the market has recently seen rapid uptake of novel anti-VEGF therapies and is experiencing a strong growth. On the other hand, the diabetic neuropathy and nephropathy segments face the barrier in and increasing number of generic competitors.

davidvilla
Télécharger la présentation

Market Outlook on 2022 Ranirestat Market Healthcare Report

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Ranirestat (Microvascular Complications of Diabetes) – Forecast and Market Analysis to 2022byGlobalData Explore all reports for “Life Sciences” market @ http://www.rnrmarketresearch.com/reports/life-sciences . © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441

  2. Ranirestat (Microvascular Complications of Diabetes) – Forecast and Market Analysis to 2022 The entire market for micro vascular complications of diabetes (MCD) diabetic nephropathy, retinopathy, and neuropathy is facing an extremely high level of unmet need across the 7MM (US, 5EU and Japan). Despite its enormous potential, the MCD market is facing the major global barrier in the sparsely populated pipeline. The diabetic retinopathy segment of the market has recently seen rapid uptake of novel anti-VEGF therapies and is experiencing a strong growth. On the other hand, the diabetic neuropathy and nephropathy segments face the barrier in and increasing number of generic competitors. Ranirestat is being developed jointly by Dainippon Sumitomo Pharma and Eisai for the treatment of diabetic neuropathy. The drug is currently in Phase III trials in Japan and recently completed Phase II/III trials in the US and Europe. Ranirestat is a selective inhibitor of AR, a key enzyme in the polyol pathway associated with the conversion of glucose to sorbitol. Request a sample copy of this report @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=147164 . © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441

  3. Ranirestat (Microvascular Complications of Diabetes) – Forecast and Market Analysis to 2022 Scope Overview of MCD, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. Detailed information on Ranirestat including product description, safety and efficacy profiles as well as a SWOT analysis. Sales forecast for Ranirestat from 2012 to 2022. Sales information covered for Japan. Complete report available @ http://www.rnrmarketresearch.com/ranirestat-microvascular-complications-of-diabetes-forecast-and-market-analysis-to-2022-market-report.html . © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441

  4. Ranirestat (Microvascular Complications of Diabetes) – Forecast and Market Analysis to 2022 Reasons to buy Understand and capitalize by identifying products that are most likely to ensure a robust return Stay ahead of the competition by understanding the changing competitive landscape for MCD Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential Make more informed business decisions from insightful and in-depth analysis of Ranirestat performance Obtain sales forecast for Ranirestat from 2012-2022 in Japan. Inquire for discount on this report @ http://www.rnrmarketresearch.com/contacts/discount?rname=147164 . © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441

  5. Ranirestat (Microvascular Complications of Diabetes) – Forecast and Market Analysis to 2022 Table Of Contents 1 Table of Contents1 Table of Contents 61.1 List of Tables 91.2 List of Figures 9 2 Introduction 102.1 Catalyst 102.2 Related Reports 11 3 Disease Overview 133.1 Etiology and Pathophysiology 153.1.1 Diabetic Nephropathy 153.1.2 Diabetic Retinopathy 173.1.3 Diabetic Neuropathy 183.2 Prognosis 193.3 Quality of Life 203.4 Symptoms 21 © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441

  6. Ranirestat (Microvascular Complications of Diabetes) – Forecast and Market Analysis to 2022 4 Disease Management 224.1 Treatment Overview 224.1.1 Diagnosis and Referrals 224.1.2 Screening 244.1.3 Treatment Guidelines 25 5 Competitive Assessment 335.1 Overview 335.2 Strategic Competitor Assessment 34 6 Opportunity and Unmet Need 386.1 Overview 386.2 Unmet Needs 396.2.1 Unified Treatment for the Microvascular Complications of Diabetes 396.2.2 Optimization of Personalized Therapy in the Microvascular Complications of Diabetes 396.2.3 Treatment for Diabetic Nephropathy that Would Prevent ESRD 416.2.4 Cardio- and Renoprotective Therapy for Diabetic Nephropathy 42 © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441

  7. Ranirestat (Microvascular Complications of Diabetes) – Forecast and Market Analysis to 2022 6.2.5 Efficient Therapy for Retinopathy 436.2.6 Convenient Administration in Diabetic Retinopathy Treatment 436.2.7 Treatment for Diabetic Neuropathy 446.3 Unmet Needs Gap Analysis 456.4 Opportunity: Therapy for the Underlying Cause of the Microvascular Complications of Diabetes 476.5 Opportunity: Patient-Tailored Therapy for the Microvascular Complications of Diabetes 476.6 Opportunity: Efficacious Therapy for Diabetic Nephropathy 486.7 Opportunity: Topical Treatment for Diabetic Retinopathy 486.8 Opportunity: Treatment for Diabetic Neuropathy 49 7 Pipeline Assessment 507.1 Overview 507.2 Promising Drugs in Clinical Development 52 Request a sample copy of this report @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=147164 . © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441

  8. Ranirestat (Microvascular Complications of Diabetes) – Forecast and Market Analysis to 2022 8 Ranirestat 548.1 Overview 548.2 Efficacy 558.3 Safety 568.4 Dosing and Formulation 568.5 Potential Clinical Positioning 568.6 Potential Commercial Positioning 578.7 Pricing and Reimbursement 578.8 SWOT Analysis 578.9 Forecast 58 9 Appendix 599.1 Bibliography 599.2 Abbreviations 639.3 Methodology 659.4 Forecasting Methodology 659.4.1 Diagnosed Patients 659.4.2 Percent Drug-Treated Patients 66 © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441

  9. Ranirestat (Microvascular Complications of Diabetes) – Forecast and Market Analysis to 2022 9.4.3 General Pricing Assumptions 669.4.4 Generic Erosion 679.4.5 Pricing of Pipeline Agents 679.5 Physicians and Specialists Included in this Study 689.6 About the Authors 709.6.1 Analyst II - CVMD 709.6.2 Therapy Director - CVMD and Infectious Disease 709.6.3 Global Head of Healthcare 719.7 About GlobalData 729.8 Disclaimer 72 List of Tables Table 1: Risk Factors for MCD 15Table 2: Symptoms of MCD 21Table 3: Diagnostic Tests and Typical Criteria for MCD 23Table 4: Treatment Guidelines for MCD 26 Table 5: Most Prescribed Drugs for MCD by Class in the 7MM, 2012 29Table 6: Leading Drug Treatments for MCD, 2013 36 © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441

  10. Ranirestat (Microvascular Complications of Diabetes) – Forecast and Market Analysis to 2022 Table 7: Overall Unmet Needs - Current Level of Attainment 38Table 8: Clinical Unmet Needs in MCD - Gap Analysis, 2012 46Table 9: MCD - Phase Pipeline, 2013 52Table 10: Comparison of Drugs in Development for MCD, 2013 53Table 11: Product Profile - Ranirestat 55Table 12: Ranirestat SWOT Analysis, 2013 57Table 13: Global Sales Forecasts ($m) for Ranirestat, 2012-2022 58Table 14: Number of High-Prescribing Physicians Surveyed 69 List of Figures Figure 1: Potential Mechanisms of Diabetes-Induced Microvascular Complications 14Figure 2: General Treatment Algorithms for MCD 27Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in MCD, 2012-2022 Inquire for discount on this report @ http://www.rnrmarketresearch.com/contacts/discount?rname=147164 . © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441

  11. Ranirestat (Microvascular Complications of Diabetes) – Forecast and Market Analysis to 2022 For more details contact Mr. PriyankTiwari:sales@rnrmarketresearch.com/ +18883915441 RnR Market Research RnRMarketResearch.com, an online repository of market  research reports, offers in-depth analysis of over 5000 market segments. RnR  Market Research library has syndicated reports by leading market research  publishers across the globe. © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441

More Related